Redhill Biopharma (RDHL) Competitors $1.51 -0.09 (-5.63%) Closing price 09/12/2025 03:54 PM EasternExtended Trading$1.49 -0.02 (-1.32%) As of 09/12/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. BIVI, FLGC, NXTC, TRAW, TXMD, SNGX, LGVN, BCDA, LPTX, and PHIOShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include BioVie (BIVI), Flora Growth (FLGC), NextCure (NXTC), Traws Pharma (TRAW), TherapeuticsMD (TXMD), Soligenix (SNGX), Longeveron (LGVN), BioCardia (BCDA), Leap Therapeutics (LPTX), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors BioVie Flora Growth NextCure Traws Pharma TherapeuticsMD Soligenix Longeveron BioCardia Leap Therapeutics Phio Pharmaceuticals BioVie (NASDAQ:BIVI) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Which has more volatility & risk, BIVI or RDHL? BioVie has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.25, indicating that its stock price is 325% more volatile than the S&P 500. Do analysts rate BIVI or RDHL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor BIVI or RDHL? In the previous week, Redhill Biopharma had 1 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Redhill Biopharma and 1 mentions for BioVie. BioVie's average media sentiment score of 1.91 beat Redhill Biopharma's score of 0.45 indicating that BioVie is being referred to more favorably in the media. Company Overall Sentiment BioVie Very Positive Redhill Biopharma Neutral Which has stronger earnings and valuation, BIVI or RDHL? Redhill Biopharma has higher revenue and earnings than BioVie. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$17.54M-$79.10-0.02Redhill Biopharma$8.04M0.43-$8.27MN/AN/A Do institutionals and insiders believe in BIVI or RDHL? 4.6% of BioVie shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 2.4% of BioVie shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BIVI or RDHL more profitable? Redhill Biopharma's return on equity of 0.00% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -89.02% -75.32% Redhill Biopharma N/A N/A N/A SummaryRedhill Biopharma beats BioVie on 8 of the 11 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.67M$2.59B$5.85B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E RatioN/A23.8575.4125.98Price / Sales0.43529.66514.54181.13Price / CashN/A171.1637.5660.44Price / Book-0.415.3712.156.29Net Income-$8.27M$32.95M$3.29B$271.07M7 Day Performance5.34%1.28%0.74%3.87%1 Month Performance8.63%6.09%4.81%4.88%1 Year Performance-86.29%-2.15%60.57%26.12% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$1.51-5.6%N/A-85.9%$3.67M$8.04M0.00210Short Interest ↑BIVIBioVie0.6715 of 5 stars$1.80+3.4%N/A-94.1%$13.11MN/A-0.0210Positive NewsGap UpFLGCFlora Growth3.2697 of 5 stars$23.59+4.8%$93.00+294.2%-33.8%$13.02M$59.51M-0.69280Positive NewsShort Interest ↓Gap UpNXTCNextCure4.7458 of 5 stars$4.85flat$25.50+425.8%-68.0%$12.98MN/A-0.1990Positive NewsShort Interest ↓Gap DownTRAWTraws Pharma1.7391 of 5 stars$1.86+3.9%N/AN/A$12.64M$230K0.0217Positive NewsShort Interest ↓TXMDTherapeuticsMD1.487 of 5 stars$1.08flatN/A-38.0%$12.50M$1.76M0.00420Positive NewsShort Interest ↓SNGXSoligenix2.7563 of 5 stars$2.66-7.0%$6.00+125.6%-14.9%$12.26MN/A-0.7020Positive NewsShort Interest ↓LGVNLongeveron3.1705 of 5 stars$0.85+7.4%$7.67+802.0%-61.0%$12.02M$2.39M-0.1420Positive NewsGap DownBCDABioCardia3.3333 of 5 stars$2.09+1.5%$25.00+1,096.2%-24.4%$11.95M$60K-1.1340Positive NewsShort Interest ↓LPTXLeap Therapeutics2.7448 of 5 stars$0.29+1.0%$3.38+1,080.5%-89.4%$11.73MN/A-0.1840Positive NewsGap DownPHIOPhio Pharmaceuticals3.0189 of 5 stars$2.12+3.9%$14.00+560.4%-24.8%$11.68MN/A-0.6510Positive NewsAnalyst UpgradeShort Interest ↓Gap Down Related Companies and Tools Related Companies BioVie Competitors Flora Growth Competitors NextCure Competitors Traws Pharma Competitors TherapeuticsMD Competitors Soligenix Competitors Longeveron Competitors BioCardia Competitors Leap Therapeutics Competitors Phio Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts